Denmark-based vaccines company Bavarian Nordic A/S (CPH:BAVA) announced on Tuesday that the US Biomedical Advanced Research and Development Authority (BARDA) has exercised contract options totalling USD143.6m for the supply of its freeze-dried JYNNEOS smallpox/mpox vaccine.

Deliveries under the agreement are scheduled for 2026.

The contract includes conversion of previously manufactured bulk vaccine and supplemental payments for doses demonstrating extended shelf life. These payments will be invoiced pro rata with the delivery of the freeze-dried formulation.

JYNNEOS, approved by the US Food and Drug Administration in March 2025, offers improved shelf life and transportation and storage benefits over the liquid-frozen version.

Bavarian Nordic has worked with the US government on vaccine development and supply since 2003.

The company has now secured DKK2,650m in revenue for its Public Preparedness business in 2025, up DKK150m due to the exercised options. Its full-year guidance remains unchanged, with projected total revenues between DKK5,700m and DKK6,700m and an EBITDA margin of 26-30%.

(USD1=DKK6.59)